Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208551 | 1.00 | PDE5A (0.40) | PDE5ALDHAPOLBPDE4APDE4B | |
| SCHEMBL25232405 | 0.85 | GABRP (0.39) | LDHAPOLBPDE4APDE4BPDE4C | |
| SCHEMBL31208509 | 0.84 | OPRK1 (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25237844 | 0.84 | OPRK1 (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25231350 | 0.81 | KDM4E (0.47) | POLBKDM4EALDH1A1HPGDSPR | |
| SCHEMBL31149461 | 0.81 | KDM4E (0.47) | POLBKDM4EALDH1A1HPGDSPR | |
| SCHEMBL22835084 | 0.79 | TRPC6 (0.47) | PDE5APOLBPDE4APDE4BPDE4C | |
| SCHEMBL29598236 | 0.79 | TRPC6 (0.47) | PDE5APOLBPDE4APDE4BPDE4C | |
| SCHEMBL25234713 | 0.76 | DPP4 (0.44) | KDM4E | |
| SCHEMBL31208526 | 0.76 | DPP4 (0.44) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | CELYN THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4448510-A1 | INHIBITORS OF MET KINASE | Kinnate Biopharma Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118742542-A | Inhibitors of MET kinase | 金耐特生物制药公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11753395-B2 | Inhibitors of MET kinase | KINNATE BIOPHARMA INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023114809-A1 | INHIBITORS OF MET KINASE | KINNATE BIOPHARMA INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595245-B2 | Inhibitors of MET kinase | MET, ABL1, ERBB2 | PDE5A 3536/4885LDHA 3248/4885POLB 1997/4885 |
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | PDE5A 3821/4885LDHA 2702/4885POLB 3282/4885 |
| US-11753395-B2 | Inhibitors of MET kinase | MET, RET, MERTK | PDE5A 3821/4885LDHA 2702/4885POLB 3282/4885 |
| US-20240067626-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | PDE5A 3821/4885LDHA 2702/4885POLB 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.